SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-20-001454
Filing Date
2020-01-21
Accepted
2020-01-21 16:05:20
Documents
1
Group Members
PONTIFAX (CAYMAN) IV, L.P.PONTIFAX (CHINA) IV, L.P.PONTIFAX (ISRAEL) 4, LIMITED PARTNERSHIPPONTIFAX 4 GP, LIMITED PARTNERSHIPPONTIFAX MANAGEMENT 4 GP (2015) LTD.TOMER KARIV

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13G sc13g1219a1pontifax_entera.htm SC 13G/A 161582
  Complete submission text file 0001213900-20-001454.txt   163188
Mailing Address C/O KITE PHARMA, INC. 2225 COLORADO AVENUE SANTA MONICA CA 90404
Business Address
Nussbaum Ran (Filed by) CIK: 0001609805 (see all company filings)

Type: SC 13G/A

Mailing Address KIRYAT HADASSAH, MINRAV BUILDING FIFTH FLOOR JERUSALEM L3 9112002
Business Address KIRYAT HADASSAH, MINRAV BUILDING FIFTH FLOOR JERUSALEM L3 9112002 972-2-532-7151
Entera Bio Ltd. (Subject) CIK: 0001638097 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-90847 | Film No.: 20536465
SIC: 2836 Biological Products, (No Diagnostic Substances)